Content developed independently by our editors and supported by our partners. Carrington Garvin had been living the fun-packed life of a typical 21-year-old in Las Vegas—dating, working for a gaming ...

In medicine, treatment goals set by physicians might differ from patient priorities. Although normalisation of laboratory parameters is a target supported by outcomes data, patient perspectives ...

Please provide your email address to receive an email when new articles are posted on . Patients with primary sclerosing cholangitis were at increased risk for colorectal cancer, regardless of whether ...

Primary sclerosing cholangitis (PSC) is a rare, chronic cholestatic liver disease of uncertain etiology characterized by the destruction of the intrahepatic and/or extrahepatic ducts through ...

– New findings to be presented at the 2025 European Association for the Study of the Liver (EASL) Congress continue to demonstrate the effectiveness of Livdelzi (seladelpar) in reducing pruritus in ...

In recent weeks, Gilead Sciences announced Health Canada's conditional approval of LYVDELZI (seladelpar) for primary biliary ...

Seladelpar is an oral, selective peroxisome proliferator-activated receptor delta agonist. Treatment with seladelpar was associated with an improvement in cholestatis markers in patients with primary ...

CNW/ - Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has approved LYVDELZI (seladelpar) for the treatment of primary ...

Topline data from the SPRING study is expected to be available in the second half of 2024. The Food and Drug Administration (FDA) has granted Fast Track designation to CM-101 for the treatment of ...

Learn about Primary Sclerosing Cholangitis (PSC), its causes, symptoms, diagnosis, and treatment options. Understand how PSC ...

—New Patents Covering Use of Nebokitug for the Treatment of Liver Diseases including Primary Sclerosing Cholangitis Issued in China and Russia Providing Coverage Up To 2041— —Further Expands ...

Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ...